Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 901–1,000 of 1,000
Child and Adolescent Psychiatric Disorders
Bostic, J. Q., & Prince, J. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50071-8 · Cited by 10
Goltz, J. S., Ivanov, I., & Rice, T. (2019) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2019.1638583 · Cited by 10
Carthy, E. R., Ross, C. C., & Murphy, D. (2021) · BJPsych Advances · doi:10.1192/bja.2021.32 · Cited by 11
“…be most extensively studied and effective in reducing irritability, aggression, hyperactivity, self-injurious behaviour, stereotypies and restricted repetitive behaviours in children with ASDs, but it has increased risk of hyperprolactinaemia, sexual side-effects and gynaecomastia (McCracken 2002).”
BackgroundEdwards, D. J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.993381 · Cited by 11
Targeted Treatments for Fragile X Syndrome
Johnson, D., Clark, C. J., & Hagerman, R. J. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_10 · Cited by 10
The Effects of Risperidone on Cognition in People With Autism Spectrum Disorder: A Systematic Review
Hutchinson, J., Folawemi, O., Bittla, P., Kaur, S., Sojitra, V., Zahra, A., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.45524 · Cited by 13
Alda, J. A., Muñoz‐Samons, D., Tor, J., Merchán‐Naranjo, J., Tapia-Casellas, C., Baeza, I., Calvo, R. M., Castro‐Fornieles, J., Martínez‐Cantarero, C., Nestares, P. A., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0151 · Cited by 11
“This effect has been emphasized especially with clozapine (Midbari et al. 2013), but also with risperidone (McCracken et al. 2002; Masi et al. 2003; Shea et al. 2004), olanzapine (Tohen et al. 2007), quetiapine (DelBello et al. 2009), and ziprasidone (Blair et al. 2005).”
Obesity Prevention and Screening
Mackey, E. R., Olson, A. M., Difazio, M. P., & Cassidy, O. L. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2015.08.009 · Cited by 14
Mollajani, R., Joghataei, M. T., & Tehrani‐Doost, M. (2019) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.9.10.380 · Cited by 12
Hongkaew, Y., Gaedigk, A., Wilffert, B., Gaedigk, R., Kittitharaphan, W., Ngamsamut, N., Limsila, P., Puangpetch, A., Sukprasong, R., & Sukasem, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743494 · Cited by 12
“Two clinical trials (McCracken et al., 2002; Shea et al., 2004) established the efficacy and tolerability of risperidone in patients with ASD and showed that risperidone significantly attenuated disruptive behaviors compared with the placebo over 8 weeks, as measured by a reduction in the irritability subscale of the…”
MethodIncrease in Valproic Acid Levels During Riluzole Treatment in an Adolescent with Autism
Veenstra-VanderWeele, J. M. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0087 · Cited by 10
“Unfortunately, the use of risperidone is associated with significant risk of adverse effects (McCracken et al. 2002).”
Pharmacotherapy of Autism and Related Disorders
Blankenship, K. M., Erickson, C. A., & McDougle, C. J. (2010) · Psychiatric Annals · doi:10.3928/00485713-20100330-06 · Cited by 11
Self-citationAntipsychotic prescribing practice among child psychiatrists and community paediatricians
Otasowie, J., Duffy, R., Freeman, J., & Hollis, C. P. (2010) · The Psychiatrist · doi:10.1192/pb.bp.108.024000 · Cited by 10
Assessment of the Integrity of Study Blindness in a Pediatric Clinical Trial of Risperidone
Vitiello, B., Davies, M., Arnold, L. E., McDougle, C. J., Aman, M. G., McCracken, J. T., Scahill, L. D., Tierney, E., Posey, D. J., Swiezy, N. B., et al. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185426.08268.92 · Cited by 10
Self-citationCharman, T. (2005) · Psychiatry · doi:10.1383/psyt.2005.4.8.81 · Cited by 14
Tardive Dyskinesia in an Autistic Patient Treated With Risperidone
Kwon, H. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.757-a · Cited by 10
Autism spectrum disorders: emerging pharmacotherapy
Bostic, J. Q., & King, B. H. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.521 · Cited by 11
Κlein, R. (2007) · BMJ · doi:10.1136/bmj.39218.599109.80 · Cited by 10
Neurexin1α knockout in rats causes aberrant social behaviour: relevance for autism and schizophrenia
Achterberg, E. J. M., Biemans, B., & Vanderschuren, L. J. M. J. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06559-z · Cited by 10
“To investigate the sensitivity to psychostimulant drugs, we assessed the hyperactivity evoked by amphetamine (that stimulates the release of dopamine, noradrenaline and serotonin), that is also used for the treatment of ADHD (Biederman and Faraone 2005; Feldman and Reiff 2014) but exacerbates positive symptoms of SCZ…”
InfluentialEffect of Adult Disapproval of Cartoon Violence on Children's Aggressive Play
Miranda, P., McCluskey, N. J., Silber, B. J., Pohle, C. M. D. V., & Bainum, C. K. (2009) · Psi Chi Journal of Psychological Research · doi:10.24839/1089-4136.jn14.2.79 · Cited by 12
Oppositional Defiant Disorder in Autism and ADHD
Mayes, S. D., Pardej, S. K., & Waschbusch, D. A. (2024) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-024-06437-9 · Cited by 13
“…2023), and psychotropic medication (Abikoff et al., 2004; Chacko et al., 2005; Connor et al., 2010; Frazier et al., 2010; Jaselskis et al., 1992; McCracken et al., 2002; McDougle et al., 2005; MTA, 1999; Nagaraj et al., 2006; Pandina et al., 2007; van der Oord et al., 2007; Waxmonsky et al.,…”
Scahill, L. D., McCracken, J. T., Bearss, K. E., Robinson, F., Hollander, E., King, B. H., Bregman, J. D., Sikich, L., Dukes, K. A., SULLIVAN, L. M., et al. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1251-8 · Cited by 9
Self-citationBelotto, K. C. R., Raposo, N. R. B., Ferreira, A. S., & Gattaz, W. F. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.11.006 · Cited by 9
Beherec, L., Quilici, G., Rosier, A., Gérardin, P., Campion, D., & Guillin, O. (2013) · L Encéphale · doi:10.1016/j.encep.2012.01.014 · Cited by 13
Ardıç, Ü. A., Küçükköse, M., İzmir, S. B. İ., & Ercan, E. S. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.1.57 · Cited by 9
Autism spectrum disorder: Practice guidelines for pharmacists
Kadi, R., Gayed, F., Kauzman, P., Ali, Z. A., Dmitriev, I., Mikhael, V., Ghabi, R., Hamamji, J., Jabbour, S., Mrchak, M., et al. (2024) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635241228495 · Cited by 11
Deciphering autism heterogeneity: a molecular stratification approach in four mouse models
Gora, C., Dudas, A., Vaugrente, O., Drobecq, L., Pecnard, E., Lefort, G., & Pellissier, L. P. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03113-5 · Cited by 13
“Although atypical antipsychotics have gained approval for targeting some co-occurring features, their ef fi cacy is often limited, and they are associated with side effects [5, 6].”
BackgroundBehavioral Disorders in Young Children with Autism Spectrum Disorder
Huete, J. M., Schmidt, J. D., & López‐Arvizu, C. (2014) · Autism and child psychopathology series · doi:10.1007/978-1-4939-0401-3_26 · Cited by 10
Kuperman, S., Calarge, C. A., Kolar, A. B., Holman, T. L., Barnett, M. J., & Perry, P. J. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300406 · Cited by 10
Quality of life in pharmacological intervention on autism spectrum disorders
Bertelli, M. O., Merli, M. P., Rossi, M., Lassi, S., Bianco, A., & Colangelo, J. (2013) · Advances in Mental Health and Intellectual Disabilities · doi:10.1108/20441281311294684 · Cited by 9
Scheithauer, M. C., Muething, C., Silva, M. R., Gerencser, K. R., Krantz, J., & Call, N. A. (2018) · International Journal of Developmental Disabilities · doi:10.1080/20473869.2018.1428521 · Cited by 10
Zhou, W., Chang, W., Yan, Y., Shen, L., Li, W., Yi, Z., & Qin, S. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.002 · Cited by 9
“Owing to its costeffectiveness, RIS has found widespread use in the treatment of SCZ and related psychoses, such as bipolar disorder, major depressive disorder and autism [20, 24, 28, 40, 44].”
Anxiety in Children with Autism Spectrum Disorder
Jennett, H. K., Vasa, R. A., & Hagopian, L. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6599-7_16 · Cited by 10
Evidence-Based Treatment Approach to Autism Spectrum Disorders
Munshi, K. R., Gonzalez–Heydrich, J., Augenstein, T. M., & D’Angelo, E. J. (2011) · Pediatric Annals · doi:10.3928/00904481-20111007-08 · Cited by 10
Prescription de la rispéridone chez l’enfant et l’adolescent
Chevreuil, C., Reymann, J., Frémaux, T., Polard, É., Séveno, T., & Bentué‐Ferrer, D. (2008) · Therapies · doi:10.2515/therapie:2008059 · Cited by 9
Autism spectrum disorder in childhood
Raznahan, A., & Bolton, P. (2008) · Medicine · doi:10.1016/j.mpmed.2008.07.005 · Cited by 9
Neuroendocrinology and Behavior
Sumiyoshi, T. (2012) · InTech eBooks · doi:10.5772/1666 · Cited by 9
Immune Modulatory Treatments for Autism Spectrum Disorder
Thom, R. P., & McDougle, C. J. (2020) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2020.100836 · Cited by 11
Self-citationNewmark, S. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00007-8 · Cited by 9
Sheridan, E., Gillespie, S. E., Johnson, C. R., Lecavalier, L., Smith, T. H., Swiezy, N. B., Turner, K. S., Pritchett, J., Mruzek, D. W., Evans, A. N., et al. (2021) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-021-00843-8 · Cited by 9
Self-citationLohr, W. D., Jawad, K. S., Feygin, Y. B., Le, J., Creel, L., Pasquenza, N., Williams, P. G., Jones, V. F., Myers, J. A., & Davis, D. W. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000673 · Cited by 10
Clinician’s Manual on Autism Spectrum Disorder
Brian, J. A., & Anagnostou, E. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-03056-2 · Cited by 12
Psychopharmacology in Children with PDD: Review of Current Evidence
Scahill, L. D., & Boorin, S. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6975-0_8 · Cited by 13
Self-citationScahill, L. D., Sukhodolsky, D. G., Anderberg, E., Dimitropoulos, A., Dziura, J. D., Aman, M. G., McCracken, J. T., Tierney, E., Hallett, V., Katz, K. H., et al. (2015) · Autism · doi:10.1177/1362361315574889 · Cited by 9
Self-citationSchwartzer, J. J., Connor, D. F., Morrison, R. L., Ricci, L. A., & Melloni, R. H. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.05.015 · Cited by 9
Deurell, M., Weischer, M., Pagsberg, A. K., & LaBianca, J. (2008) · Nordic Journal of Psychiatry · doi:10.1080/08039480801985096 · Cited by 9
Autism: Where We Have Been, Where We Are Going
Rapin, I. (2005) · Wiley eBooks · doi:10.1002/9780470939352.ch27 · Cited by 12
Effects of Cannabidiol Isolated or in Association With Risperidone in an Animal Model of Autism
da Costa, M. D. A., Fernandes, G. Z., Maiochi, E., Ebs, M. F. P., Darós, F. D. S., Bolan, S. J., Costa, R. R. N., de Rezende, V. L., da Silva, G. C., de Bitencourt, R. M., et al. (2024) · Developmental Neurobiology · doi:10.1002/dneu.22955 · Cited by 12
“However, it was not able to improve social withdrawal and social interest (McCracken et al. 2002).”
Common Genetic Variants in Autism Spectrum Disorders
Anney, R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391924-3.00010-7 · Cited by 19
Autism Intervention Research: From the Reviews to Implications for Practice
Freeman, S. F. N., Paparella, T., & Goods, K. S. (2009) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)38008-2 · Cited by 9
Eissa, N., Venkatachalam, K., Jayaprakash, P., Yuvaraju, P., Falkenstein, M., Stark, H., & Sadek, B. S. (2022) · Pharmaceuticals · doi:10.3390/ph15080929 · Cited by 10
“Although not seen in all studies [25], risperidone demonstrated a significant effect on stereotyped behavior in autistic individuals [26,27], and improved social behavior, as evaluated by the Childhood Autism Rating Scale [25,28].”
Management of neurological symptoms in Lesch-Nyhan disease: A systematic review
Krajewski, O., Opiełka, M., Urbanowicz, K., Chojnowski, K., Kochany, P., Pawłowski, K., Tomaszewska, J., Peters, G. J., Smolenski, R. T., & Mazurkiewicz‐Bełdzińska, M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105847 · Cited by 8
“…an atypical antipsychotic primarily indicated in schizophrenia, however, it is used in the short-term management of behavioral disturbances in autistic disorder (Pandina et al., 2007; McCracken et al., 2002), Tourette syndrome (Dion et al., 2002) and Cornelia De Lange syndrome (Kline et al., 2018).”
BackgroundYang, F., Kang, L., & Zou, C. (2025) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2025.24944 · Cited by 14
Pharmacology of Autism Spectrum Disorder
Greydanus, D. E., Kaplan, G., & Patel, D. R. (2015) · Contemporary clinical neuroscience · doi:10.1007/978-1-4939-2190-4_9 · Cited by 8
Samsel, C. B., & Muriel, A. C. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26220 · Cited by 8
Vannucchi, G., Perugi, G., & Masi, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-26276-1_7 · Cited by 9
Shakibaei, F., & Jelvani, D. (2023) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000544 · Cited by 9
Court, J. M. (2013) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12241 · Cited by 9
Common psychiatric comorbidities and their assessment
Ameis, S. H., & Szatmári, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-03056-2_3 · Cited by 14
Scahill, L. D. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0573-7 · Cited by 8
Self-citationOff-label psychotropic prescribing for young persons in medium security
Haw, C., & Stubbs, J. H. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105102 · Cited by 11
Dietary Considerations in Autism: Identifying a Reasonable Approach
Johnson, T. W. (2006) · Topics in Clinical Nutrition · doi:10.1097/00008486-200607000-00008 · Cited by 10
Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review
Poweleit, E. A., Colestock, M., Kantemneni, E. C., Strawn, J. R., Patino, L. R., DelBello, M. P., & Ramsey, L. B. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0106 · Cited by 10
“…antagonists (DSRAs)—formerly designated as second-generation antipsychotics—in youth with psychosis, mania, irritability associated with autism spectrum disorders, and Tourette’s disorder (McCracken et al. 2002; Findling et al. 2008; Kumra et al. 2008; Fraguas et al. 2011; Sallee et al. 2017).”
Kara, I., & Penner, M. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0096 · Cited by 10
“Aripiprazole and risperidone are two Food and Drug Administration-approved SGAs used to treat irritability and aggression in children with autism spectrum disorder (ASD), with several trials demonstrating their efficacy (Accardo 2003; Marcus et al. 2009; Owen et al. 2009).”
BackgroundContemporary assessment and pharmacotherapy of Tourette syndrome
Scahill, L. D., Erenberg, G., Berlin, C. M., Budman, C. L., Coffey, B. J., Jankovic, J. J., Kiessling, L. S., King, R. A., Kurlan, R., Lang, A. E., et al. (2006) · Neurotherapeutics · doi:10.1007/bf03207049 · Cited by 41
Self-citationFenerci, R. L. B., Jenkins, G. A., Gilbert, A. C., Schettini, E., Musella, K. E., MacPherson, H. A., Kim, K. L., Kudinova, A. Y., Radoeva, P. D., & Dickstein, D. P. (2022) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12887 · Cited by 8
Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic
Lim, S., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27165088 · Cited by 11
Psychopharmacology in children with intellectual disability
Bramble, D. J. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005587 · Cited by 9
Psychopharmacology of Neurodevelopmental Disorders in Children
Singh, J., & Santosh, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-3619-1_18 · Cited by 9
Houghton, R., van den Bergh, J. P., Law, K., Liu, Y., & de Vries, F. (2021) · Autism Research · doi:10.1002/aur.2541 · Cited by 10
“…extrapyramidal disorders (6%–15% for aripiprazole; 12%–28% for risperidone; 0%–13% placebo) over 6 to 8 weeks, with exact estimates varying with dose and event definition (Ichikawa et al., 2017; Kent et al., 2013; Marcus et al., 2009; McCracken et al., 2002; Owen et al., 2009; Shea et al., 2004).”
BackgroundResultInfluentialNeurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_36-1 · Cited by 10
Self-citationAutism or Schizophrenia: A Diagnostic Dilemma in Adults with Intellectual Disabilities
Akande, E., Xenitidis, K., MULLENDER, S., ROBERSTON, D., & Gorman, J. M. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200405000-00009 · Cited by 8
Controversies Surrounding Pediatric Psychopharmacology
Steinberg-Epstein, R., Book, T. M., & Wigal, S. B. (2011) · Advances in Pediatrics · doi:10.1016/j.yapd.2011.03.002 · Cited by 8
Risperidone and late onset tics
Feroz-Nainar, C., & Roy, M. (2006) · Autism · doi:10.1177/1362361306063297 · Cited by 8
Goëb, J.-L., Ravary, M., Lallie, C., Kechid, G., Jardri, R., Bonelli, F., Lenfant, A.-Y., Baleyte, J., Mille, C., & Delion, P. (2009) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2009.05.006 · Cited by 8
Ward, C. L., Childress, A. C., Martinko, K., Chen, D., Larsen, K. G., Shah, A., Sheridan, P. L., Hefting, N., & Knutson, J. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0118 · Cited by 7
“…in the placebo group showed a larger improvement than seen in prior studies (mean ABC-I reductions of – 8.9 in the current study vs – 3.5 to – 8.4 in the aripiprazole, ris-peridone, and lurasidone studies) (Loebel et al., 2016; Marcus et al., 2009; McCracken et al., 2002; Owen et al., 2009).”
InfluentialHarris, K., Fosdick, C., Zappia, K. J., Dominick, K. C., & Lamy, M. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0104 · Cited by 7
“Medications do not treat the core symptoms of autism; however, the atypical antipsychotics risperidone (McCracken et al., 2002) and aripiprazole (Shea et al., 2004) are FDA-approved for treatment of irritability in autistic individuals.”
Neurological Adverse Effects of Antipsychotic Medication in Children and Young People
Besag, F., Vasey, M. J., Hollis, C. P., & Taylor, D. M. (2026) · Pediatric Drugs · doi:10.1007/s40272-025-00730-5 · Cited by 8
Jamadagni, P., Dai, Y., Liu, Y., Mendes, H. W., Pruitt, A., Khan, S., Yang, L., Huang, T.-C., Huang, X., Deans, P. J. M., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518846123 · Cited by 10
“Given growing evidence implicating mitochondrial biology in ASDs (35), we sought to gain insight into molecular mechanisms contributing to the behavioral rescue by LEVO, a mitochondrial modulator and carnitine supplement.”
InfluentialBarzotto, M. B. M., Gonçalves, M. M. D. Q., Bueno, F. G., Virtuoso, S., & Sanches, A. C. C. (2023) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv15n12-112 · Cited by 7
Rao, P., Zepf, F. D., Chakrabarti, I., & Sigalas, P. D. (2016) · Translational Developmental Psychiatry · doi:10.3402/tdp.v4.28537 · Cited by 7
Valdovinos, M. G., Epperson, C., & Johnson, C. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.08.010 · Cited by 8
Périsse, D., Guinchat, V., Hellings, J. A., & Baghdadli, A. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.10.011 · Cited by 13
Self, T. L., Hale, L. S., & Crumrine, D. (2010) · Language Speech and Hearing Services in Schools · doi:10.1044/0161-1461(2009/08-0106 · Cited by 10
Multiple Psychiatric Diagnoses Common in Privately Insured Children on Atypical Antipsychotics
Halloran, D. R., Swindle, J. P., Takemoto, S. K., & Schnitzler, M. A. (2010) · Clinical Pediatrics · doi:10.1177/0009922809347369 · Cited by 9
Antochi, R. M., & Stavrakaki, C. (2004) · Psychiatric Annals · doi:10.3928/0048-5713-20040301-09 · Cited by 8
Wang, F., Wen, F., Yu, L., Yan, J., Liu, J., Li, Y., & Cui, Y. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000349 · Cited by 7
“Autistic children and adolescents with hyperactivity symptoms had higher rates of school behavior problems, including aggressive and oppositional behavior (Mulligan et al., 2009; Kotte et al., 2013).”
BackgroundAripiprazole Decreases Irritability in 12 out of 14 Youth with Autism Spectrum Disorders
Maloney, A. E., Mick, E. O., & Frazier, J. A. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0143 · Cited by 9
“In 2006, the FDA approved ris-peridone for the treatment of irritability in youth with autism based on two, 8 week randomized controlled trials (McCracken et al. 2002; Shea et al. 2004).”
Clinical Management of Adolescents with Autism
Deokar, A. M., Huff, M. B., & Omar, H. Α. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.07.006 · Cited by 7
Advances in the Pharmacotherapy of Pervasive Developmental Disorders (PDD)
Stigler, K. A., Posey, D. J., & McDougle, C. J. (2003) · Child and Adolescent Psychopharmacology News · doi:10.1521/capn.8.7.6.24962 · Cited by 7
Self-citationMental Health Services for Children and Adolescents: Challenges and Opportunities
Joshi, P. T. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3193 · Cited by 10
Arnold, L. E. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12097 · Cited by 7
Self-citationA Genetic Etiology of Pervasive Developmental Disorder Guides Treatment
Solomon, M., Hessl, D. R., Chiu, S., Hagerman, R. J., & Hendren, R. L. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.4.575 · Cited by 10
“Although risperidone is the only medication with an autism indication (18), her mother was concerned about its potential to cause weight gain and other side effects, such as increased prolactin.”
BackgroundCoocurrencia entre ansiedad y autismo. Las hipótesis del error social y de la carga alostática
Pérez, I. P. (2013) · Revista de Neurología · doi:10.33588/rn.56s01.2012652 · Cited by 21
Vollmer, T. R., Bosch, A. B., Ringdahl, J. E., & Rapp, J. T. (2014) · Wiley eBooks · doi:10.1002/9781118326077.ch7 · Cited by 8
Marcotulli, D., Foulkes, L., & Stringaris, A. K. (2025) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.70055 · Cited by 11
“In the same interval, however, one in six gains at least 7% body weight and one in two experiences sedation (NNH (cid:1) 6 and 2, respectively) (McCracken et al., 2002).”
Zheng, R., Huang, S., Feng, P., Liu, S., Jiang, M., Li, H., Zheng, P., Mi, Y., & Li, E. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1557174 · Cited by 6
“More importantly, blocking postsynaptic dopamine and serotonin receptors might be beneficial in children with ASD (McCracken et al., 2002).”
Ahire, C. G., & Kaur, G. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101037 · Cited by 9
“Risperidone is approved by the FDA (Food and Drug Administration) to be used for the treatment of pediatric patients aged ≥ 5 years (McCracken et al., 2002).”
Joshi, G., Gönenç, A., DiSalvo, M., Faraone, S. V., Ceranoglu, T. A., Yule, A. M., Uchida, M., McDougle, C. J., & Wozniak, J. R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.34927 · Cited by 7
Self-citationSharma, R., Tiwari, A., Rahi, S., & Mehan, S. (2020) · Current Psychopharmacologye · doi:10.2174/1389203721999200820165117 · Cited by 6
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.